Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Acasti Pharma (ACST)

Acasti Pharma (ACST)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 30,184
  • Shares Outstanding, K 90,209
  • Annual Sales, $ 0 K
  • Annual Income, $ -39,290 K
  • 60-Month Beta 1.66
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.50
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 02/14/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -0.09
  • Number of Estimates 3
  • High Estimate -0.08
  • Low Estimate -0.12
  • Prior Year -0.17
  • Growth Rate Est. (year over year) +47.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2500 +33.84%
on 03/19/20
0.4594 -27.17%
on 03/04/20
-0.1054 (-23.95%)
since 03/03/20
3-Month
0.2500 +33.84%
on 03/19/20
2.5400 -86.83%
on 01/07/20
-1.9954 (-85.64%)
since 01/03/20
52-Week
0.2500 +33.84%
on 03/19/20
3.0800 -89.14%
on 12/23/19
-0.6654 (-66.54%)
since 04/03/19

Most Recent Stories

More News
Acasti Pharma Submits FDA Meeting Request on Schedule, and FDA Meeting Expected in the Second Half of June

Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST - TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate...

ACST : 0.3346 (-3.01%)
ACST.VN : 0.470 (-6.00%)
Acasti Pharma Awarded Notice of Allowance for Additional Composition of Matter and Method of Use Patents in the United States and Mexico

Patent upheld in Japan following opposition filings and subsequently allowed

ACST : 0.3346 (-3.01%)
ACST.VN : 0.470 (-6.00%)
Acasti Receives NASDAQ Notification Regarding Minimum Bid Requirements

Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST - TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate...

ACST : 0.3346 (-3.01%)
ACST.VN : 0.470 (-6.00%)
Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2020

Acasti Pharma Inc. ("Acasti or the "Company") (NASDAQ: ACST - TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre...

ACST : 0.3346 (-3.01%)
ACST.VN : 0.470 (-6.00%)
Acasti Pharma Schedules Third Quarter Fiscal 2020 and Business Update Conference Call

Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST - TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate...

ACST : 0.3346 (-3.01%)
ACST.VN : 0.470 (-6.00%)
Acasti Pharma Provides Update on TRILOGY 1 and TRILOGY 2 Phase 3 Trials of CaPre

Investigation underway into unexpected and inconsistent findings that may have negatively impacted results reported in TRILOGY 1

ACST : 0.3346 (-3.01%)
ACST.VN : 0.470 (-6.00%)
AstraZeneca to End Phase III Study on Fish Oil Heart Drug

AstraZeneca (AZN) to discontinue STRENGTH study on its fish-oil pill Epanova in mixed dyslipidaemia on recommendation of an independent Data Monitoring Committee

MRK : 76.25 (-0.81%)
AZN : 43.96 (+0.46%)
AMRN : 4.78 (-8.43%)
ACST : 0.3346 (-3.01%)
Neptune Provides Updates on Non-Core Investments

Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (Nasdaq: NEPT) (TSX: NEPT), a health and wellness company focused on extraction, purification and formulation of cannabinoids, would like to...

NEPT : 1.1600 (-3.33%)
NEPT.TO : 1.65 (-2.37%)
ACST : 0.3346 (-3.01%)
Acasti Pharma Reports Topline Results for TRILOGY 1 Phase 3 Trial of CaPre

Reports 30.5% and 36.7% reduction in triglyceride levels, compared with baseline, among patients receiving CaPre at 12 and 26 weeks respectively, as well as 42.2% reduction in triglyceride levels among...

ACST : 0.3346 (-3.01%)
ACST.VN : 0.470 (-6.00%)
IIROC Trading Resumption - ACST

Trading resumes in:

ACST : 0.3346 (-3.01%)
ACST.VN : 0.470 (-6.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade ACST with:

Business Summary

Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R)...

See More

Key Turning Points

2nd Resistance Point 0.3896
1st Resistance Point 0.3621
Last Price 0.3346
1st Support Level 0.3150
2nd Support Level 0.2954

See More

52-Week High 3.0800
Fibonacci 61.8% 1.9989
Fibonacci 50% 1.6650
Fibonacci 38.2% 1.3311
Last Price 0.3346
52-Week Low 0.2500

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar